Explore
Validate
LearnNBP1-76769
antibody from Novus Biologicals
Targeting: CD274
B7-H, B7-H1, B7H1, PD-L1, PDCD1LG1, PDL1
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [14]
- Comments [0]
- Validations
- Western blot [4]
- Immunohistochemistry [3]
- Flow cytometry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- NBP1-76769 - Provider product page
- Provider
- Novus Biologicals
- Proper citation
- Novus Cat#NBP1-76769, RRID:AB_11024101
- Product name
- Rabbit Polyclonal PD-L1 Antibody
- Antibody type
- Polyclonal
- Description
- Peptide affinity purified. PD-L1 antibody has no cross-reactivity to PD-L2.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 0.1 mg
- Concentration
- 1 mg/ml
- Storage
- Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Submitted references Identification of primordial germ cell-like cells as liver metastasis initiating cells in mouse tumour models.
Adipocytes promote tumor progression and induce PD-L1 expression via TNF-α/IL-6 signaling.
Autophagy inhibition enhances PD-L1 expression in gastric cancer.
Rationally designed peptide-conjugated gold/platinum nanosystem with active tumor-targeting for enhancing tumor photothermal-immunotherapy.
Fraxinellone has anticancer activity in vivo by inhibiting programmed cell death-ligand 1 expression by reducing hypoxia-inducible factor-1α and STAT3.
Dexmedetomidine Mitigates Microglia-Mediated Neuroinflammation through Upregulation of Programmed Cell Death Protein 1 in a Rat Spinal Cord Injury Model.
Competing endogenous RNA network analysis of CD274, IL‑10 and FOXP3 co‑expression in laryngeal squamous cell carcinoma.
Lactoferricin B reverses cisplatin resistance in head and neck squamous cell carcinoma cells through targeting PD-L1.
Immune Checkpoint Ligand PD-L1 Is Upregulated in Pulmonary Lymphangioleiomyomatosis.
Hedgehog signaling induces PD-L1 expression and tumor cell proliferation in gastric cancer.
A regulatory role for the co-chaperone FKBP51s in PD-L1 expression in glioma.
Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies.
Placental immune editing switch (PIES): learning about immunomodulatory pathways from a unique case report.
Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma.
Liu C, Ma Z, Cai Z, Zhang F, Liu C, Chen T, Peng D, Xu X, Lin HK
Cell discovery 2020;6:15
Cell discovery 2020;6:15
Adipocytes promote tumor progression and induce PD-L1 expression via TNF-α/IL-6 signaling.
Li Z, Zhang C, Du JX, Zhao J, Shi MT, Jin MW, Liu H
Cancer cell international 2020;20:179
Cancer cell international 2020;20:179
Autophagy inhibition enhances PD-L1 expression in gastric cancer.
Wang X, Wu WKK, Gao J, Li Z, Dong B, Lin X, Li Y, Li Y, Gong J, Qi C, Peng Z, Yu J, Shen L
Journal of experimental & clinical cancer research : CR 2019 Mar 29;38(1):140
Journal of experimental & clinical cancer research : CR 2019 Mar 29;38(1):140
Rationally designed peptide-conjugated gold/platinum nanosystem with active tumor-targeting for enhancing tumor photothermal-immunotherapy.
Yang Q, Peng J, Shi K, Xiao Y, Liu Q, Han R, Wei X, Qian Z
Journal of controlled release : official journal of the Controlled Release Society 2019 Aug 28;308:29-43
Journal of controlled release : official journal of the Controlled Release Society 2019 Aug 28;308:29-43
Fraxinellone has anticancer activity in vivo by inhibiting programmed cell death-ligand 1 expression by reducing hypoxia-inducible factor-1α and STAT3.
Xing Y, Mi C, Wang Z, Zhang ZH, Li MY, Zuo HX, Wang JY, Jin X, Ma J
Pharmacological research 2018 Sep;135:166-180
Pharmacological research 2018 Sep;135:166-180
Dexmedetomidine Mitigates Microglia-Mediated Neuroinflammation through Upregulation of Programmed Cell Death Protein 1 in a Rat Spinal Cord Injury Model.
He H, Zhou Y, Zhou Y, Zhuang J, He X, Wang S, Lin W
Journal of neurotrauma 2018 Nov 1;35(21):2591-2603
Journal of neurotrauma 2018 Nov 1;35(21):2591-2603
Competing endogenous RNA network analysis of CD274, IL‑10 and FOXP3 co‑expression in laryngeal squamous cell carcinoma.
Sun J, Lian M, Ma H, Wang R, Ma Z, Wang H, Zhai J, Meng L, Feng L, Bai Y, Cui X, Fang J
Molecular medicine reports 2018 Mar;17(3):3859-3869
Molecular medicine reports 2018 Mar;17(3):3859-3869
Lactoferricin B reverses cisplatin resistance in head and neck squamous cell carcinoma cells through targeting PD-L1.
Zhang P, Liu J, Li W, Li S, Han X
Cancer medicine 2018 Jul;7(7):3178-3187
Cancer medicine 2018 Jul;7(7):3178-3187
Immune Checkpoint Ligand PD-L1 Is Upregulated in Pulmonary Lymphangioleiomyomatosis.
Maisel K, Merrilees MJ, Atochina-Vasserman EN, Lian L, Obraztsova K, Rue R, Vasserman AN, Zuo N, Angel LF, Gow AJ, Kang I, Wight TN, Eruslanov E, Swartz MA, Krymskaya VP
American journal of respiratory cell and molecular biology 2018 Dec;59(6):723-732
American journal of respiratory cell and molecular biology 2018 Dec;59(6):723-732
Hedgehog signaling induces PD-L1 expression and tumor cell proliferation in gastric cancer.
Chakrabarti J, Holokai L, Syu L, Steele NG, Chang J, Wang J, Ahmed S, Dlugosz A, Zavros Y
Oncotarget 2018 Dec 21;9(100):37439-37457
Oncotarget 2018 Dec 21;9(100):37439-37457
A regulatory role for the co-chaperone FKBP51s in PD-L1 expression in glioma.
D'Arrigo P, Russo M, Rea A, Tufano M, Guadagno E, Del Basso De Caro ML, Pacelli R, Hausch F, Staibano S, Ilardi G, Parisi S, Romano MF, Romano S
Oncotarget 2017 Sep 15;8(40):68291-68304
Oncotarget 2017 Sep 15;8(40):68291-68304
Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies.
Gravelle P, Burroni B, Péricart S, Rossi C, Bezombes C, Tosolini M, Damotte D, Brousset P, Fournié JJ, Laurent C
Oncotarget 2017 Jul 4;8(27):44960-44975
Oncotarget 2017 Jul 4;8(27):44960-44975
Placental immune editing switch (PIES): learning about immunomodulatory pathways from a unique case report.
Bronchud MH, Tresserra F, Xu W, Warren S, Cusido M, Zantop B, Zenclussen AC, Cesano A
Oncotarget 2016 Dec 13;7(50):83817-83827
Oncotarget 2016 Dec 13;7(50):83817-83827
Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma.
Aguilar LK, Shirley LA, Chung VM, Marsh CL, Walker J, Coyle W, Marx H, Bekaii-Saab T, Lesinski GB, Swanson B, Sanchez D, Manzanera AG, Aguilar-Cordova E, Bloomston M
Cancer immunology, immunotherapy : CII 2015 Jun;64(6):727-36
Cancer immunology, immunotherapy : CII 2015 Jun;64(6):727-36
No comments: Submit comment
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Western Blot: PD-L1/B7-H1 Antibody [NBP1-76769] - B7-H1/PD-L1/CD274 Antibody [NBP1-76769] - Analysis of PD-L1 in Raji cell lysate with PD-L1 antibody at (A) 0.5 and (B) 1 ug/mL.
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Western Blot: PD-L1 Antibody [NBP1-76769] - Expression of CD274 in Human melanoma SK-MEL-28 cell line upon treatment with 200 mM ethanol. Dilution: 1:1,000 in PBS with 5% BSA. Secondary Ab: anti-Rabbit IgG 1:5,000. This image was submitted via customer Review.
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Western Blot: PD-L1 Antibody [NBP1-76769] - "Figure 4 Validation with PD-L1 overexpression in 293 cells Loading: Lysates/proteins at 15 ug per lane. Lane 1: non-transfected 293 cells. Lane 2: PD-L1 overexpressed 293 cells. Antibodies: NBP1-76769 (1 ug/mL). 1 h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate.
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Western Blot: PD-L1 Antibody [NBP1-76769] - Independent Antibody Validation (IAV) via Protein Expression Profile Loading: 15 ug of lysates per lane. Antibodies: NBP1-76769 (2 ug/mL), PD-L1 (2 ug/mL), and beta-actin (1 ug/mL), 1 h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit and or anti-mouse IgG HRP conjugate at 1:10000 and 1:5000 dilution, respectively.
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Immunohistochemistry-Paraffin: PD-L1 Antibody [NBP1-76769] - B7-H1/PD-L1/CD274 Antibody [NBP1-76769] - Human tonsil tissue with PD-L1 antibody at 5 ug/ml.
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Immunohistochemistry-Paraffin: PD-L1 Antibody [NBP1-76769] - Staining of human heart tissue with antibody at 2.5 ug/mL.
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Immunohistochemistry-Paraffin: PD-L1 Antibody [NBP1-76769] - PD-L1/B7-H1 Antibody [NBP1-76769] - PD-L1 in rat heart tissue with at 5 ug/mL.
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Flow Cytometry: PD-L1 Antibody [NBP1-76769] - B7-H1/PD-L1/CD274 Antibody [NBP1-76769] - Analysis of A-20 cells using B7-H1/PD-L1/CD274 antibody at 0.5 ug/ml. Green: Isotype control. Red : B7-H1/PD-L1/CD274 antibody.
